Abstract
Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an umodified state.
Similar content being viewed by others
References
S. S. Boiko, V. P. Zherdev, A. A. Dvoryaninov, et al.,Eksp. Klin. Farmakol.,60, No. 12, 669–672 (1997).
J. M. Addison, D. Burston, J. W. Payne, et al.,Clin. Sci.,49, 969–978 (1975).
J. P. F. Bai and G. L. Amidon,Pharmacol. Res.,9, 969–978 (1992).
W. A. Banks and A. J. Kastin,Brain Res. Bull.,15, 287–292 (1985).
D. J. Boullin, R. E. Crempton, C. E. Heading, and D. Pelling,Clin. Sci.,45, 48–58 (1973).
V. Canapathy and G. Burkharolt,J. Biol. Chem.,254, 8954–8959 (1984).
V. Canapathy and F. H. Leibach,Am. J. Physiol.,249, 9153–9160 (1985).
J. Dyer, R. B. Beechey, J. P. Gorvel, et al.,J. Biochem.,269, 565–571 (1990).
J. Esposito,Handbook of Experimental Pharmacology, Ed. T. Z. Crsaky, Berlin (1984), vol. 70, pt. 2, pp. 567–611.
G. Fricker and J. Drewe,J. Pept. Sci.,2, No. 4, 195–211 (1996).
D. M. Matthews,Contr. Infusion Ther. Clin. Nutr.,17, 6–53 (1987).
E. B. Semrad and E. B. D. Chang,Am. J. Physiol.,352, 312–315 (1987).
E. E. Sterchi and G. F. Woddley,Clin. Chem.,102, 49–56 (1980).
K. Takaori, J. Burston, and M. Donowitz,Biochem. Biophys. Res. Commun. 137, 682–687 (1983).
Author information
Authors and Affiliations
Additional information
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 129, No. 4, pp. 426–429, April, 2000
Rights and permissions
About this article
Cite this article
Boiko, S.S., Ostrovskaya, R.U., Zherdev, V.P. et al. Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration. Bull Exp Biol Med 129, 359–361 (2000). https://doi.org/10.1007/BF02439270
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02439270